[7] L. K. Sharp and M. S. Lipsky, “Screening for Depression Across the Lifespan: A Review of Measures for Use in Primary Care Settings,” American Family Physician, Vol. 66, No. 6, 2002, pp. 1001-1009.

has been cited by the following article:

• TITLE: An Epidemiologic Study of Depressive Symptoms among Cardiometabolic Department Patients in México

  AUTHORS: Jaime Carranza-Madrigal, Sonia M. López-Correa, Jesús Alveano-Hernández

  KEYWORDS: Cardiometabolic, Depression, Prevalence

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.2 No.2, May 27, 2011

  ABSTRACT: Background. This study estimated the prevalence of depressive symptoms among cardiometabolic department patients in México. Methods. To identify patients with depressive symptoms, we used the Beck’s Depression Inventory (BDI). We analyzed data from consecutive adult patients who attended during a year to a Cardiometabolic Department in México and described the demographic, metabolic and vascular status differences between depressive and non-depressive patients. The estimates are based on a total of 180 patients aged 22 to 83 years. Results. There was a depressive symptoms prevalence rate of 60.5%. Compared with non-depressive patients, depressive patients were more likely to be obese, and to have dysglucemia, hypercholesterolemia, hypoalphalipoproteinemia, microalbuminuria, high uric acid levels, carotid atherosclerosis, insulin resistance and metabolic syndrome. Conclusions. Our data suggest that prevalence of depression is elevated among cardiometabolic patients in México. Depression probably plays a role in cardiometabolic physiopathogenic, and must be intentionally assessed in cardiometabolic patients in order to treat it and to improve the cardiometabolic treatment response and adherence.